Sodium channel protein type 10 subunit alpha

Description:

Description
  • Accession: Q9Y5Y9
  • Swissprot: SCNAA_HUMAN
  • Organism: Homo sapiens
  • Gene: SCN10A
  • Target class: Ion channel

Drug Relations:

benzocaine
A surface anesthetic that acts by preventing transmission of impulses along NERVE FIBERS and at NERVE ENDINGS. Bioactivity details MOA
chloroprocaine
Bioactivity details MOA
cinchocaine
A local anesthetic of the amide type now generally used for surface anesthesia. It is one of the most potent and toxic of the long-acting local anesthetics and its parenteral use is restricted to spinal anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1006) Bioactivity details MOA
dyclonine
minor descriptor (66-83); on-line & Index Medicus search PROPIOPHENONES (66-83); RN given refers to parent cpd; structure Bioactivity details MOA
eslicarbazepine acetate
Eslicarbazepine acetate is extensively converted to eslicarbazepine, which is considered to be responsible for therapeutic effects in humans. The precise mechanism(s) by which eslicarbazepine exerts anticonvulsant activity is unknown but is thought to involve inhibition of voltage-gated sodium channels. Bioactivity details MOA
ethotoin
Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to prevent the spread of seizure activity rather than to abolish the primary focus of seizure discharges. Bioactivity details MOA
lamotrigine
A phenyltriazine compound, sodium and calcium channel blocker that is used for the treatment of SEIZURES and BIPOLAR DISORDER. Bioactivity details MOA
lidocaine
A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE. Bioactivity details MOA
mephenytoin
An anticonvulsant effective in tonic-clonic epilepsy (EPILEPSY, TONIC-CLONIC). It may cause blood dyscrasias. Bioactivity details MOA
mexiletine
Antiarrhythmic agent pharmacologically similar to LIDOCAINE. It may have some anticonvulsant properties. Bioactivity details MOA
orphenadrine
A muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm. Bioactivity details MOA
oxybuprocaine
Bioactivity details MOA
phenazopyridine
A local anesthetic that has been used in urinary tract disorders. Its use is limited by problems with toxicity (primarily blood disorders) and potential carcinogenicity. Bioactivity details MOA
procainamide
A class Ia antiarrhythmic drug that is structurally-related to PROCAINE. Bioactivity details MOA
procaine
A local anesthetic of the ester type that has a slow onset and a short duration of action. It is mainly used for infiltration anesthesia, peripheral nerve block, and spinal block. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1016). Bioactivity details MOA
proparacaine
Bioactivity details MOA
ropivacaine
An anilide used as a long-acting local anesthetic. It has a differential blocking effect on sensory and motor neurons. Bioactivity details MOA
rufinamide
The precise mechanism(s) by which rufinamide exerts its antiepileptic effect is unknown. The results of in vitro studies suggest that the principal mechanism of action of rufinamide is modulation of the activity of sodium channels and, in particular, prolongation of the inactive state of the channel. Bioactivity details MOA
tocainide
An antiarrhythmic agent which exerts a potential- and frequency-dependent block of SODIUM CHANNELS. Bioactivity details MOA
ambroxol
A metabolite of BROMHEXINE that stimulates mucociliary action and clears the air passages in the respiratory tract. It is usually administered as the hydrochloride. Bioactivity details MOA